Simplist^® ready-to-administer prefilled syringes

Simplist is a single unit dose prefilled syringe requiring no assembly at the point of care.* Designed for efficient medication delivery and ease of use, Simplist helps reduce waste potential and eliminate steps where errors can occur.^1,2

By the numbers

We help customers reduce waste with product size optimization.
Based on hospitals analyzed, we found institutions benefited in these areas*:

2,066,619

Over Two Million Waste Transactions Identified

Fentanyl (n = 176)

Hydromorphone (n = 181)

Morphine (n = 155)

53%

Estimated average annual waste event reductions

461,049 transactions

Estimated annual waste event reductions

9,759 hours

Estimated annual time saved*

Waste Events

Healthcare providers must discard any excess controlled substances if the quantity dispensed exceeds the prescribed dose. Hospital protocols may differ on how this procedure is carried out.

Data Ananlysis Process

By analyzing data from previous instances of waste in healthcare facilities, it is possible to calculate potential reductions by aligning product size with clinical practice.

Definitions

^*Data on file provided by real clients. Hospitals analyzed N = 183, Fentanyl Citrate Injection, USP n = 176, Hydromorphone HCI Injection, USP n = 181, Morphine Sulfate Injection, USP n = 155.

Fresenius Kabi provides no guarantee of the likelihood that you will achieve similar results if you use our products.

Estimated annual time saved reflects one nurse’s time to waste and does not include witness time required.

Calculate the cost of narcotic waste in your institution

Upload your automated dispensing cabinet waste report

Simple, anonymous, and secure.
Get instant analysis of controlled substance waste

See product-level waste and diversion insights within minutes.
Discover opportunities to reduce diversion risk and time

Use the report to implement change, and request a full consultation with the Director of Integrated Pharmacy Solutions for deeper analysis.

Start your own waste analysis

Simplist is associated with a 4x lower error rate^* compared to traditional practice, including a cartridge-based syringe system³

^*A prospective, multisite, observational study of IV push medication preparation and administration compared the error rates between ready-to-administer products and traditional practice, including a cartridge-based syringe system and vial and syringe. Simplist was the only RTA delivery system used in the study. Study limitations include only a select number of sites (3) and steps observed.

Less preparation

Discover Simplist

Reducing Diversion Risk in Medication Waste

Watch the video

Guide to Implement Simplist Prefilled Syringes

Watch the video

Turn Your Waste Reports into Action

Upload your report

Simplist in the OR

Ephedrine 25 mg per 5 mL and 50 mg per 10 mL +RFID^®

Succinylcholine 100 mg per 5 mL and 200 mg per 10 mL +RFID

Glycopyrrolate, Dexamethasone and Ondansetron syringes +RFID^®

Dexamethasone 4 mg per mL +RFID

Glycopyrrolate 0.2 mg per mL +RFID

Naloxone 0.4 mg per mL and 2 mg per 2 mL

Simplist Packaging

State-of-the-Art Manufacturing

Clinical Education and Training

Glycopyrrolate 0.6 mg per 3 mL

Omnicell Controlled Substance Dispenser

Webinar: Reducing Diversion Risk in Medication Waste. Marilin Wong, PharmD, MBA, DPLA Director, Integrated Pharmacy Solutions Fresenius Kabi; Adam Beeler, PharmD, MS VP, Strategy MIDAS Healthcare Solutions; Jeffrey Wahl Co-Founder & General Counsel MIDAS Healthcare Solutions

Reducing Diversion Risk in Medication Waste

Learn how leading hospitals are transforming diversion prevention from a reactive process into a proactive safety strategy.

Watch the video

Matt Gimbar: Senior Associate Director of Pharmacy, UI-Health

Guide to Implement Simplist Prefilled Syringes

Discover how UI Health implemented Simplist ready-to-administer prefilled syringes seamlessly across pharmacy, nursing, and administration.

Watch the video

Turn Your Waste Reports into Action

Our automated tool quickly analyzes your hospital’s controlled substance waste.

Upload your report

Simplist in the OR

Simplist in the OR

Ephedrine 25 mg per 5 mL and 50 mg per 10 mL +RFID^®

Succinylcholine 100 mg per 5 mL and 200 mg per 10 mL +RFID

Glycopyrrolate, Dexamethasone and Ondansetron syringes +RFID

Glycopyrrolate, Dexamethasone and Ondansetron syringes +RFID^®

Dexamethasone 4 mg per mL +RFID

Dexamethasone 4 mg per mL +RFID

Glycopyrrolate 0.2 mg per mL +RFID

Glycopyrrolate 0.2 mg per mL +RFID

Naloxone 0.4 mg per 1 mL and 2 mg per 2 mL

Naloxone 0.4 mg per mL and 2 mg per 2 mL

Simplist microvault blister packaging

Simplist Packaging

Simplist state-of-the-art manufacturing

State-of-the-Art Manufacturing

Simplist clinical education and training

Clinical Education and Training

Glycopyrrolate 0.6 mg per 3mL Simplist syringe

Glycopyrrolate 0.6 mg per 3 mL

Omnicell controlled substance dispenser

Omnicell Controlled Substance Dispenser

IMPORTANT SAFETY INFORMATION

Succinylcholine Chloride Injection, USP

IMPORTANT SAFETY INFORMATION

WARNING: VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST, AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS

Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.
When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of Succinylcholine Chloride Injection, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. In the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.
Reserve the use of Succinylcholine Chloride Injection in pediatric patients for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible.

CONTRAINDICATIONS

In patients with skeletal muscle myopathies
In patients with known hypersensitivity to succinylcholine
After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury
In patients with a personal or familial history or suspected genetic susceptibility to malignant hyperthermia

WARNINGS AND PRECAUTIONS

Anaphylaxis: Severe anaphylactic reactions to neuromuscular blocking agents, including succinylcholine, have been reported. Some cases have been life-threatening and fatal. Take necessary precautions, such as the immediate availability of appropriate emergency.
Risk of Death due Medication Errors: Unintended administration of Succinylcholine Chloride Injection may result in paralysis, respiratory arrest and death. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings.
Hyperkalemia: Succinylcholine Chloride Injection may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia.
Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies.
Bradycardia: Intravenous bolus administration may result in profound bradycardia or, rarely asystole. The incidence is higher following a second dose of succinylcholine. Pretreatment with anticholinergic agents (e.g. atropine) may reduce the occurrence of bradyarrhythmias.

ADVERSE REACTIONS

Adverse reactions reported with succinylcholine are cardiac arrest, malignant hyperthermia, arrhythmias, bradycardia, tachycardia, hypertension, hypotension, hyperkalemia, prolonged respiratory depression or apnea.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Drugs that May Enhance the Neuromuscular Blocking Action of Succinylcholine: promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma cholinesterase activity.

INDICATIONS AND USE

Succinylcholine Chloride Injection is a depolarizing neuromuscular blocker indicated in adults and pediatric patients:

As an adjunct to general anesthesia
To facilitate tracheal intubation
To provide skeletal muscle relaxation during surgery or mechanical ventilation

This Important Safety Information does not include all the information needed to use SUCCINYLCHOLINE CHLORIDE INJECTION, USP safely and effectively. Please see full prescribing information, including BOXED WARNING, for SUCCINYLCHOLINE CHLORIDE INJECTION, USP 100 mg per 5 mL and 200 mg per 10 mL.

*Medications that are administered intramuscularly or subcutaneously require a needle to be attached to the syringe.

References:

Connect with us

Sign up below to receive the latest Simplist news and updates.

For Additional Information

To place an order, contact your Sales Representative, or call Custom Service at 1.888.386.1300.

IMPORTANT SAFETY INFORMATION

Succinylcholine Chloride Injection, USP

IMPORTANT SAFETY INFORMATION

WARNING: VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST, AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS

Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.
When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of Succinylcholine Chloride Injection, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. In the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.
Reserve the use of Succinylcholine Chloride Injection in pediatric patients for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible.

CONTRAINDICATIONS

In patients with skeletal muscle myopathies
In patients with known hypersensitivity to succinylcholine
After the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury
In patients with a personal or familial history or suspected genetic susceptibility to malignant hyperthermia

WARNINGS AND PRECAUTIONS

Anaphylaxis: Severe anaphylactic reactions to neuromuscular blocking agents, including succinylcholine, have been reported. Some cases have been life-threatening and fatal. Take necessary precautions, such as the immediate availability of appropriate emergency.
Risk of Death due Medication Errors: Unintended administration of Succinylcholine Chloride Injection may result in paralysis, respiratory arrest and death. Confirm proper selection of intended product and avoid confusion with other injectable solutions that are present in critical care and other clinical settings.
Hyperkalemia: Succinylcholine Chloride Injection may induce serious cardiac arrhythmias or cardiac arrest due to hyperkalemia.
Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies.
Bradycardia: Intravenous bolus administration may result in profound bradycardia or, rarely asystole. The incidence is higher following a second dose of succinylcholine. Pretreatment with anticholinergic agents (e.g. atropine) may reduce the occurrence of bradyarrhythmias.

ADVERSE REACTIONS

Adverse reactions reported with succinylcholine are cardiac arrest, malignant hyperthermia, arrhythmias, bradycardia, tachycardia, hypertension, hypotension, hyperkalemia, prolonged respiratory depression or apnea.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

Drugs that May Enhance the Neuromuscular Blocking Action of Succinylcholine: promazine, oxytocin, aprotinin, certain non-penicillin antibiotics, quinidine, β-adrenergic blockers, procainamide, lidocaine, trimethaphan, lithium carbonate, magnesium salts, quinine, chloroquine, isoflurane, desflurane, metoclopramide, terbutaline, and drugs that reduce plasma cholinesterase activity.

INDICATIONS AND USE

Succinylcholine Chloride Injection is a depolarizing neuromuscular blocker indicated in adults and pediatric patients:

As an adjunct to general anesthesia
To facilitate tracheal intubation
To provide skeletal muscle relaxation during surgery or mechanical ventilation

This Important Safety Information does not include all the information needed to use SUCCINYLCHOLINE CHLORIDE INJECTION, USP safely and effectively. Please see full prescribing information, including BOXED WARNING, for SUCCINYLCHOLINE CHLORIDE INJECTION, USP 100 mg per 5 mL and 200 mg per 10 mL.